Search

Your search keyword '"Bursi, S."' showing total 115 results

Search Constraints

Start Over You searched for: Author "Bursi, S." Remove constraint Author: "Bursi, S."
115 results on '"Bursi, S."'

Search Results

5. Genome-wide association study identifies an early onset pancreatic cancer risk locus

9. A multifactorial score for pancreatic ductal adenocarcinoma risk prediction

10. Genome-wide association study identifies an early onset pancreatic cancer risk locus

11. SLC22A3 polymorphisms may influence overall patient survival-PANDORA study

14. Occhio al Drusen

17. 'Quando scendono le ovaie...'

35. First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine ( C ), irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI): a pilot study by the Gruppo Oncologico Nord Ovest (G.O.N.O.)

38. EPA-1226 – Consultation-liaison psychiatry and the “women wellness project”: analysis of the association between cardiovascular risk factors and psychiatric symptoms in postmenopausal women.

40. 7036 Phase II study with pharmacodynamic evaluation of docetaxelprednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC)

41. Phase II study of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first-line treatment in castration resistant prostate cancer (CRPC) patients (Pts)

42. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer

44. Docetaxel (D) plus prednisone (P) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line chemotherapy in metastatic hormone refractory prostate cancer (HRPC): Phase II clinical trial with pharmacodynamic evaluation

46. 3051 POSTER Phase II trial of sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC)

47. 3063 POSTER Capecitabine (C), in combination with irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.)

48. The combination of capecitabine (C), irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.)

49. Phase II study of sequential chemotherapy with cisplatin (P) in combination with infusional 5FU/LV (PFL) followed by irinotecan (Ir) + 5FU/LV (IrFL) followed by docetaxel (T) + 5FU/LV (TFL) in patients (pts) with metastatic gastric carcinoma (MGC) by the Gruppo Oncologio Nord-Ovest (GONO)

Catalog

Books, media, physical & digital resources